On May 22, 2023, DiaMedica Therapeutics Inc. announced that the Company filed on May 19, 2023 a complete clinical hold response with the U.S. Food and Drug Administration (the FDA") requesting that the clinical hold imposed on the Company's pivotal Phase 2/3 clinical trial of DM199 for acute ischemic stroke (AIS"), or ReMEDy2 study, be lifted. Included in the response is a protocol amendment designed to incorporate a reduced dose for the intravenous administration of DM199 and incorporate certain additional measures to reduce the risk of severe hypotension in study participants. Also, on May 22, 2023, the Company made available an investor presentation regarding the status of the ReMEDy2 study that the Company intends to use in connection with presentations at conferences and meetings (the Investor Presentation).

The Investor Presentation is furnished as Exhibit 99.1 to this report shall not be deemed to be "filed" with the United States Securities and Exchange Commission for purposes of Section 18 of the United States Securities Exchange Act of 1934, as amended (the Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any filings made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such filing. The information contained in this Current Report on Form 8-K and the exhibit hereto is summary information that is intended to be considered in the context of the Company's United States Securities and Exchange Commission (the SEC") filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report and the exhibit hereto, although it may do so from time to time as its management believes is warranted.